Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > REGULATORY
REGULATORY
- MHLW Panel Backs Orphan Drug Designation for Opdivo for Hodgkin’s Lymphoma
February 29, 2016
- MHLW Advisory Panel Supports Novartis’s Ceritinib, AZ’s Osimertinib
February 29, 2016
- PMDA Reviewing Risks of Intestinal Obstruction for Loxoprofen
February 29, 2016
- Kaketsuken Allowed to Ship Japanese Encephalitis Vaccine
February 29, 2016
- Drug Makers, Distributors Rolling Up Their Sleeves for Mandatory Barcode Labeling
February 26, 2016
- MHLW Grants Orphan Designation to Takeda’s MM Drug Ixazomib
February 26, 2016
- MHLW Panel Backs Approval of Sanofi’s Antiepileptic Drug, OKs Cymbalta’s New Indication by Unanimous Vote
February 25, 2016
- Industry Must Find Logical Reasons to Dodge Re-Pricing amid Growing Pressure on Huge Sellers
February 24, 2016
- Possible Price Slash for Big-Sellers Looms as 2017 Tax Hike Nears; All Eyes on Opdivo
February 24, 2016
- MHLW Taskforce on Vaccines and Blood Products Holds 2nd Meeting
February 23, 2016
- Pricing Debate Spills Over into MHLW Safety Panel, Member Warns Opdivo Costs Could Jeopardize State Finances
February 22, 2016
- Next Invitation for Sakigake Pathway Might Not Happen Until FY2017, Designations Likely to Decrease: Official
February 18, 2016
- Terms of Emergency Deliveries Emerge as New Challenge amid Growing Generic Use
February 17, 2016
- Add Rhabdomyolysis to Nexium Label: MHLW
February 17, 2016
- LDP Lawmaker Questions “Huge Seller” Re-Pricing
February 17, 2016
- Cause of Post-HPV Vaccine Symptoms Can’t Be Immediately Elucidated: Govt
February 16, 2016
- 22 Firms Win Approvals for Zyprexa Generics for June Listing; Kipres AGs Also OK’ed
February 16, 2016
- MHLW to Hold Supplementary Review on Cymbalta’s New Pain Indication
February 16, 2016
- MHLW Panel to Discuss Sanofi’s Antiepileptic Drug Vigabatrin on Feb. 24
February 16, 2016
- MHLW Advisory Committee to Discuss 2 Lung Cancer Drugs on Feb. 26
February 16, 2016
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…